Clinical Trial

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Study acronym: ASPEN
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.
Protocol Amendment History 3 changes
notable Trial sites expanded: 10 -> 18 locations 2026-07-07
notable Trial sites expanded: 4 -> 10 locations 2026-05-30
critical Recruitment opened 2026-04-23
Trial Details
NCT Number NCT07441876
Lead Sponsor BioMarin Pharmaceutical
Conditions Achondroplasia
Enrollment 160 participants
Start Date 2026-04-20
Primary Completion 2029-06 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-24